NEW YORK/FRANKFURT, Feb 10 (Reuters) - (This Feb. 10 story has been refiled to say 'LOEs (loss of exclusivity),' not 'LOEs (levels of evidence),' in paragraph 13) Merck, in a statement ...

Patients with advanced kidney cancer who received an experimental vaccine after their tumors were removed were still ...

Merck KGaA, the German healthcare and technology group, is in advanced talks to acquire U.S. cancer and rare diseases ...

Germany-based Merck KGaA (OTC:MKGAF) (OTC:MKKGY) reacted to press reports and confirmed advanced discussions with SpringWorks ...

Following an initial report from Reuters, Merck KGaA confirmed that it is in talks with SpringWorks for a potential ...

After a slow 2024, dealmaking in the U.S. healthcare sector is picking up. Springworks has a market value of $3 billion.

Stamford-based SpringWorks Therapeutics, a commercial-stage biotech company developing treatments for rare diseases and ...

A transaction for Springworks would rank as one of the biggest pharma deals for Merck in recent years and boost its ongoing ...

EST Merck KGaA (MKGAY) in talks to buy SpringWorks Therapeutics (SWTX), Reuters reportsMaximize Your Portfolio with Data Driven ...

Merck KGaA said it’s in advanced talks to purchase SpringWorks Therapeutics Inc., sending shares of the US cancer and rare ...